drugset / Trial / NCT02533375

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

NCT02533375

Phase 3 Completed 10 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.

Timeline

Start
2015-09-28
Primary completion
2016-09-15
Completion
2017-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous